药品、化妆品开发商Pierre Fabre Laboratories宣布从Antares Therapeutics收购PFL-721和PFL-241的全球权利-动脉网

Pierre Fabre Laboratories Strengthen R&D Portfolio and Announce the Acquisition of the Worldwide Rights for PFL-721 and PFL-241

CISION 等信源发布 2025-06-16 16:00



可切换为仅中文







PFL-721 and PFL-241 are mutant-specific EGFR inhibitors with best-in-class potential, being developed as treatment options for emergent and unmet medical needs in non-small cell lung cancer ('NSCLC')

PFL-721和PFL-241是具有同类最佳潜力的突变型EGFR抑制剂，正在开发作为治疗非小细胞肺癌（NSCLC）中新兴且未满足医疗需求的选择。

CASTRES,

卡斯特尔，

France

法国

，

June 16, 2025

2025年6月16日

/PRNewswire/ -- Pierre Fabre Laboratories are pleased to announce the acquisition from Antares Therapeutics, Inc. ('Antares'), a spin-out of Scorpion Therapeutics, Inc., of the worldwide rights for PFL-721 and PFL-241 (formerly known as STX-721 and STX-241, respectively). Under the terms of the agreement, Pierre Fabre Laboratories will expand its previous agreement with Scorpion Therapeutics to hold the global rights for both assets and will be leading the clinical development of both programs..

/PRENewswire/ -- 皮埃尔·法布雷实验室欣然宣布，从天蝎座治疗公司（Scorpion Therapeutics, Inc.）分拆出的安塔瑞斯治疗公司（Antares Therapeutics, Inc.，简称“安塔瑞斯”）手中收购了PFL-721和PFL-241（之前分别称为STX-721和STX-241）的全球权利。根据协议条款，皮埃尔·法布雷实验室将扩大与天蝎座治疗公司的先前协议，获得这两项资产的全球权利，并主导这两个项目的临床开发。

继续阅读

View PDF

查看PDF

Pierre Fabre Laboratories Strengthen R&D Portfolio and Announce the Acquisition of the Worldwide Rights for PFL-721 and PFL-241

皮尔法伯实验室加强研发组合并宣布收购PFL-721和PFL-241的全球权利

PFL-721 is a mutant-specific EGFR exon 20 and HER2 exon 20 inhibitor, soon to transition to dose optimization within a first-in-human trial in NSCLC. PFL-241 is a mutant-specific, brain penetrant, 4th generation EGFR inhibitor, currently in dose escalation in a first-in-human trial, to address C797S resistance mutations in NSCLC patients..

PFL-721是一种针对EGFR第20外显子和HER2第20外显子的突变特异性抑制剂，即将在非小细胞肺癌的首次人体试验中进入剂量优化阶段。PFL-241是一种突变特异性、可穿透血脑屏障的第四代EGFR抑制剂，目前正在进行首次人体试验的剂量递增，以解决非小细胞肺癌患者的C797S耐药突变问题。

NSCLC is the most common sub-type of lung cancer and various EGFR mutations are the most frequent drivers of NSCLC, occurring in approximately 14-38 percent of tumors, depending on geography.

非小细胞肺癌是最常见的肺癌亚型，各种EGFR突变是非小细胞肺癌最常见的驱动因素，约14%-38%的肿瘤存在此类突变，具体比例因地域而异。

[1], [2], [3]

'With this agreement with Antares, Pierre Fabre Laboratories now own the global rights for all the assets within our R&D portfolio: exarafenib, PFL-002 (formerly VERT-002), PFL-721 and PFL-241. The R&D team is fully engaged and committed to progress the clinical development of these programs, aiming at providing novel and differentiated precision medicines to patient populations with significant unmet needs.' said .

“通过与Antares的这项协议，皮尔法伯实验室现在拥有我们研发组合中所有资产的全球权利：exarafenib、PFL-002（原VERT-002）、PFL-721和PFL-241。研发团队全力以赴，致力于推进这些项目的临床开发，目标是为存在显著未满足需求的患者群体提供新颖且差异化的精准药物。”

Francesco Hofmann

弗朗切斯科·霍夫曼

, Head of Research and Development for Medical Care at Pierre Fabre Laboratories.

皮埃尔·法布雷实验室医疗保健研发主管。

About Pierre Fabre Laboratories

关于皮埃尔·法布雷实验室

Pierre Fabre Laboratories is the world's second-largest dermo-cosmetics company and one of

皮尔法伯实验室是全球第二大皮肤化妆品公司，并且是其中之一。

Europe's

欧洲的

leading pharmaceutical laboratories. Its Dermo-cosmetics & Personal Care portfolio includes international brands such as Eau Thermale Avène, Ducray, Klorane, A-Derma, René Furterer, Même Cosmetics, Darrow and Elgydium. Its Medical Care activity covers 5 main therapeutic fields: oncology, dermatology, rare diseases, primary care and family health care..

领先的制药实验室。其皮肤化妆品和个人护理产品组合包括国际品牌，如雅漾温泉水、Ducray、Klorane、A-Derma、René Furterer、Même Cosmetics、Darrow和Elgydium。其医疗保健业务涵盖5个主要治疗领域：肿瘤学、皮肤病学、罕见病、初级保健和家庭保健。

[1]

The Prevalence of EGFR Mutation in Patients with Non-Small Cell Lung Cancer, Oncotarget,

非小细胞肺癌患者中EGFR突变的流行率，Oncotarget，

October 2016

2016年10月

[2]

EGFR Mutation Incidence in Non-Small Cell Lung Cancer, J Cancer Res.,

非小细胞肺癌中EGFR突变的发病率，癌症研究杂志，

August 2015

2015年8月

[3]